midazolam in dextrose 5% — Class II drug recall D-1075-2023
Terminated recall by Central Admixture Pharmacy Services Inc, reported 2023-08-09, distributed nationwide. Lack of assurance of sterility: Lack of validation data for sanitization cycles
| Recall number | D-1075-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Central Admixture Pharmacy Services Inc, San Diego, CA, United States |
| Recall initiated | 2023-07-17 |
| Classified | 2023-08-03 |
| Reported by FDA | 2023-08-09 |
| Terminated | 2025-03-21 |
| Distributed | Nationwide (US) |
| Quantity | 621 syringes |
| Reason classes | sterility |
| NDC | 71286-4036-01 |
| Lot numbers | 17-270666, 17-270879, 17-271669, 17-272287, 17-272366, 17-272991, 17-273512 |
| Expiration dates | 2023-07-18, 2023-07-20, 2023-08-02, 2023-08-14, 2023-08-15, 2023-08-24, 2023-09-04 |
Product
midazolam in dextrose 5%, 50 mg /50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-4036-1
Reason for recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1075-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.